Jiao Shiping, Liu Wenjie, Wu Minqing, Peng Cheng, Tang Hailin, Xie Xiaoming
Department of Breast Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China.
Department of Breast Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China Department of Cancer Prevention Center, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.
Cancer Biomark. 2015;15(2):115-23. doi: 10.3233/CBM-140443.
Existing reports showed loss of Nrdp1, an E3 ubiquitin ligase, promoted breast cancer malignancy because of failure to deregulate ErbB3. However, the correlation between Nrdp1 expression with clinical data is still unknown.
We explored the predictive value of Nrdp1 regarding the clinical outcome of patients and the benefit of adjuvant anthracycline-based chemotherapy.
113 primary breast cancer samples were obtained during surgery and the patients received average 10-year follow-up. We obtained Nrdp1 and ErbB3 expressions by immunohistochemistry.
Nrdp1 expression correlates with overall survival and disease-free survival of patients, with a hazard ratio of 0.237 (p=0.001) and 0.280 (p< 0.001) respectively. Additionally Nrdp1 correlates inversely with ErbB3 expression in tumor tissue (p=0.009). However the prognosis of Nrdp1 was not solely dependent on its regulation of ErbB3 degradation since there was also a significant correlation between Nrdp1 and overall survival (p=0.005) in ErbB3-negative patients. In patients who received anthracycline-based chemotherapy, low Nrdp1 expression indicated decreased disease-free survival (p=0.006) and high rates of metastasis and/or recurrence (p<0.001).
Nrdp1 may serve as a useful biomarker for the clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer.The prognosis of Nrdp1 was not solely dependent on its deregulation of ErbB3.
现有报告显示，E3泛素连接酶Nrdp1的缺失因无法调控ErbB3而促进了乳腺癌的恶性发展。然而，Nrdp1表达与临床数据之间的相关性仍不清楚。
我们探讨了Nrdp1对患者临床结局的预测价值以及基于蒽环类药物辅助化疗的益处。
手术期间获取113例原发性乳腺癌样本，患者接受了平均10年的随访。我们通过免疫组织化学获得Nrdp1和ErbB3的表达。
Nrdp1表达与患者的总生存期和无病生存期相关，风险比分别为0.237（p=0.001）和0.280（p<0.001）。此外，Nrdp1与肿瘤组织中ErbB3的表达呈负相关（p=0.009）。然而，Nrdp1的预后并不完全取决于其对ErbB3降解的调控，因为在ErbB3阴性患者中，Nrdp1与总生存期之间也存在显著相关性（p=0.005）。在接受基于蒽环类药物化疗的患者中，低Nrdp1表达表明无病生存期缩短（p=0.006），转移和/或复发率高（p<0.001）。
Nrdp1可能是预测乳腺癌患者临床结局及基于蒽环类药物辅助化疗疗效的有用生物标志物。Nrdp1的预后并不完全取决于其对ErbB3的调控失常。
